ASXTravelan Phase 2 Study Results Published
other announcement
IMC
Pharmaceuticals, Biotechnology & Life Sciences
Immuron
- Short interest
- 0.14%
- +0.12 pp 30d
- as of 21 July 2025
- Reported shorts
- 380K
- Shares on issue
- 268.220M
Immuron (IMC) News
Latest articles and price-sensitive announcements with AI sentiment classification.
KalkineImmuron (ASX:IMC) Advances IMM-529 Partnering Strategy with Triple-Action CDI Approach
Highlights Immuron is positioning IMM-529 for external partnering after securing FDA IND approval for a Phase 2 clinical study. IMM-529 targets three components of C. difficile infectionToxin B, vegetative cells and sporesin a single oral biologic. Preclinical studies recorded approximately 80% survival in prevention and treatment models and around 90% in relapse models. Immurons partnering model shifts future development and commercialisation funding towards prospective licensees while opening...
Appendix 4G and Corporate Governance Statement
other announcement
Presentation to Coffee Microcaps Conference
other announcement
Why Is Immuron (ASX:IMC) Securing US Route for PROIBS?
Highlights Immuron is in focus after its latest market disclosure clarified current operating priorities. The news is relevant to early stage delivery, funding resilience and commercial progress, with delivery and financial resilience central to the market reading. Independent reporting adds context while the company material remains the primary factual reference. Immuron (ASX:IMC) is drawing current ASX attention after its latest market disclosure added detail about its operating direction a...
Google NewsImmuron (ASX:IMC) Calmino Deal Turns Travelan Ramp Into a Portfolio Story - Stocks Down Under
Immuron (ASX:IMC) Calmino Deal Turns Travelan Ramp Into a Portfolio Story Stocks Down Under
Immuron (ASX:IMC) Shares Retreat While Travelan Sales Growth Extends Through FY26 - Kalkine
Immuron (ASX:IMC) Shares Retreat While Travelan Sales Growth Extends Through FY26 Kalkine
Immuron (ASX: IMC) Pushes IMM-529 Forward with FDA Clearance and Partnering Strategy
Highlights Immuron has secured FDA IND approval for IMM-529 to enter a Phase 2 clinical study in C. difficile infection. IMM-529 targets Toxin B, vegetative cells and spores through a three-pronged antibody approach. Pre-clinical studies show activity across prevention, treatment and recurrence models of C. difficile infection. Immuron has engaged Pullan Consulting as it seeks a strategic partner to fund development through commercialisation. Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is advanci...
Immuron (ASX:IMC) Pursues Strategic Partnership to Advance FDA IND-Cleared IMM-529
Highlights Immuron has appointed Pullan Consulting to secure a strategic partner for the clinical development and commercialisation of IMM-529. IMM-529 has received FDA IND application clearance, enabling a Phase 2 clinical trial for the prevention or treatment of Clostridioides difficile infection. The Phase 2 study will evaluate IMM-529 alongside the standard of care in up to 60 patients with first-episode or recurrent CDI. An independent market assessme...
Immuron (ASX:IMC) Targets Growth Through Commercial and Clinical Expansion
Key Highlights Immuron is focusing on expanding OTC product sales and pursuing strategic partnering opportunities for its late-stage clinical assets. The company reported global sales revenue of AUD 5.7 million year-to-date in FY26, as of March 2026, up 7% on the prior corresponding period. Travelan® sales in Australia rose 15% during the third quarter of FY26. The company is pursuing partnering opportunities for IMM-124E and IMM-529 to reduce development funding requirements. IMM-529 remai...
Immuron (ASX:IMC) Steps into Spotlight at Emerging Growth Conference
Highlights Immuron CEO Steven Lydeamore will present at the Emerging Growth Conference via a virtual session on 7 May 2026. The virtual presentation will provide an opportunity to engage with investors and market participants. Immuron is a commercial and clinical-stage Australian biopharmaceutical company focused on orally delivered antibody therapies. The company markets its flagship products Travelan® and Protectyn®, both listed on the Australian Register of Therapeutic Goods (TGA). ...
Immuron (ASX:IMC) Strengthens Growth Story with IMM-529 Advancing to Phase 2
Highlights Immuron combines commercial products and pipeline assets around an oral antibody platform. IMM-529 is advancing toward Phase 2 following FDA approval of its investigational new drug application and initiation of a partnering process.. The therapy targets recurrent CDI through a differentiated three-target mechanism. Immuron reported sales growth across major markets in the March 2026 period. Partnering to progress clinical activity keep IMM-529 central to the company narrative. Imm...
Immuron (ASX:IMC) Shares Rally on Q3 Sales Boost and Retail Expansion
Highlights Immuron reported global Q3 sales of AUD 1.5 million, up 16% year-on-year. Australia led performance with AUD 0.9 million in quarterly sales, rising 15%. Canada recorded over 100% Q3 growth compared to the prior corresponding period and 82% growth quarter-on-quarter. Immuron Limited (ASX:IMC) shares surged over 24% to AUD 0.036 in morning trading on 17 April 2026 after the company released its third-quarter (Q3) sales update. The biopharmaceutical group reported year-on-year growth ...
Immuron (ASX:IMC) Targets Multi-Billion-Dollar Travel Health Opportunity with Travelan®
Highlights Immuron has developed IMM-124E (Travelan®) leveraging its polyclonal antibody platform. Travelan® is positioned as a preventive solution for travelers’ diarrhea caused by bacterial pathogens. The product is approved or licensed across key markets, including Australia, Canada, and the United States. IMM-124E contains antibodies derived from hyper-immune bovine colostrum, enabling targeted gut activity. Backed by a scalable immunotherapy platform, Travelan® anchors Im...
What’s Driving Immuron’s (ASX:IMC; NASDAQ:IMRN) Pipeline Progress and FY26 Outlook?
Highlights Immuron has reported HY26 sales of A$4.2 million, reflecting a 5% increase on HY25. Travelan® helps prevent travellers’ diarrhea by targeting harmful gut bacteria. The company received FDA approval for IMM-529 Investigational New Drug application for Phase 2 trial. Immuron secured a new US Department of Defense award targeting Campylobacter and Shigella. The company expanded its product offering with the launch of ProIBS® in Australia. Net assets increased to A$13.07 mi...
Steven Lydeamore to present at Emerging Growth Conference
other announcement
Notice of Extraordinary General Meeting and Proxy Form
other announcement
Uniformed Services University to Release Topline Data
other announcement